Pharmaceutical Drugs Coverage

Coronavirus (COVID-19) Current Therapy Market Definition

Coronavirus (COVID-19) current therapy refers to the range of pharmaceutical treatments and therapeutic interventions used to manage and treat the symptoms of COVID-19, reduce viral load and prevent severe outcomes such as hospitalization or death. These therapies target the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus, associated inflammation and complications caused by the disease, aiming to improve recovery rates and minimize long-term health impacts. The coronavirus (COVID-19) current therapy market consists of sales, by entities (organizations, sole traders, or partnerships), of coronavirus (COVID-19) current therapy that are utilized by a wide demographic of patients diagnosed with the virus, encompassing mild, moderate and severe cases. These treatments are employed in both acute and long-term care scenarios, ranging from early-stage intervention to advanced care for critically ill patients. The therapies are often used in combination with supportive measures such as oxygen therapy, mechanical ventilation and other critical care practices, complementing the mainstay antiviral and anti-inflammatory drugs.

Coronavirus (COVID-19) Current Therapy Market Definition

Coronavirus (COVID-19) current therapy refers to the range of pharmaceutical treatments and therapeutic interventions used to manage and treat the symptoms of COVID-19, reduce viral load and prevent severe outcomes such as hospitalization or death. These therapies target the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus, associated inflammation and complications caused by the disease, aiming to improve recovery rates and minimize long-term health impacts. The coronavirus (COVID-19) current therapy market consists of sales, by entities (organizations, sole traders, or partnerships), of coronavirus (COVID-19) current therapy that are utilized by a wide demographic of patients diagnosed with the virus, encompassing mild, moderate and severe cases. These treatments are employed in both acute and long-term care scenarios, ranging from early-stage intervention to advanced care for critically ill patients. The therapies are often used in combination with supportive measures such as oxygen therapy, mechanical ventilation and other critical care practices, complementing the mainstay antiviral and anti-inflammatory drugs.

Ngenla Market Definition

Ngenla refers to a long-acting human growth hormone (somatrogon) developed for the treatment of growth hormone deficiency (GHD) in children and adults. It is used to improve growth and manage growth-related disorders by replacing the natural growth hormone in individuals with inadequate production. The main indication types of ngenla are growth hormone deficiency, turner syndrome, prader-willi, and small for gestational age. Growth hormone deficiency is a condition where the body does not produce enough growth hormone, leading to poor growth in children and adults. The several distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies, and it is used by various end users such as pediatric patients and adult patients.

Ngenla Market Segmentation

The ngenla market covered in this report is segmented – 1) By Indication: Growth Hormone Deficiency; Turner Syndrome; Prader-Willi; Small For Gestational Age 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies 3) By End User: Pediatric Patients; Adult Patients

Pombiliti Market Definition

Pombiliti, also known by its generic name cipaglucosidase alfa, is an enzyme replacement therapy (ERT) developed for the treatment of late-onset pompe disease (LOPD). Pompe disease is a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), which leads to the buildup of glycogen in muscle cells, resulting in progressive muscle weakness and respiratory issues. The main indications of pombiliti are late-onset pompe disease. Late-onset pompe disease is a rare genetic disorder caused by a deficiency of an enzyme called acid alpha-glucosidase, which leads to the buildup of glycogen in muscles and other tissues. Pombiliti is specifically designed to address the enzyme deficiency in adults with Late-onset pompe disease, improving muscle function and quality of life. It is administrated through the route of intravenous infusion and is distributed through various channels such as direct sales, pharmaceutical wholesalers, and online pharmacies and utilized by end users such as hospitals and clinics.

Pombiliti Market Segmentation

The pombiliti market covered in this report is segmented – 1) By Indication: Late-Onset Pompe disease 2) By Administration Route: Intravenous Infusion 3) By Distribution Channel: Direct Sales; Pharmaceutical Wholesalers; Online Pharmacies 4) By End-User: Hospitals; Clinics

Praluent Market Definition

Praluent is a monoclonal antibody used to treat high cholesterol levels, specifically low-density lipoprotein (LDL) cholesterol, known as bad cholesterol. It is used for treating adults with primary hypercholesterolemia or mixed dyslipidemia and reducing cardiovascular risk in patients with established heart disease. The main indications for praluent are primary hypercholesterolemia, mixed dyslipidemia, and established atherosclerotic cardiovascular disease (ASCVD). Primary hypercholesterolemia is a genetic condition marked by elevated levels of LDL cholesterol in the blood. Praluent, which contains alirocumab, treats this condition by blocking the PCSK9 protein, thereby reducing LDL cholesterol levels. It is distributed through various channels such as hospitals and clinics, retail pharmacies, and specialty pharmacies and is utilized by end users including ambulatory care and homecare.

Praluent Market Segmentation

The praluent market covered in this report is segmented – 1) By Indication: Primary Hypercholesterolemia; Mixed Dyslipidemia; Established Atherosclerotic Cardiovascular Disease (ASCVD) 2) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Specialty Pharmacies 3) By End-User: Ambulatory Care; Home Care

Pregnyl Market Definition

Pregnyl is a medication containing the hormone human chorionic gonadotropin (hCG), which is used in various medical treatments. It is prescribed to stimulate ovulation in women undergoing fertility treatments, to improve male fertility by boosting testosterone and sperm production, and to treat undescended testicles in boys. It is administered via injection and should be used under medical supervision. The main indications for pregnyl are fertility treatments in women, male infertility, and hypogonadotropic hypogonadism. Fertility treatments using pregnyl for women are primarily aimed at stimulating ovulation in women have difficulty conceiving due to conditions such as polycystic ovary syndrome (PCOS) or other ovulatory disorders. Pregnyl contains human chorionic gonadotropin (hCG), which mimics the natural hormone that triggers ovulation. It is distributed through various channels such as hospitals pharmacies, retail pharmacies, and online pharmacies and is utilized by fertility clinics, research institutions and others.

Pregnyl Market Segmentation

The pregnyl market covered in this report is segmented – 1) By Indication: Fertility Treatments In Women; Male Infertility; Hypogonadotropic Hypogonadism 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies 3) By End-User: Fertility Clinics; Research Institutions; Other End-Users

Regkirona (regdanvimab) Market Definition

Regkirona refers to regdanvimab, a monoclonal antibody treatment for COVID-19 used to prevent the progression of mild to moderate symptoms in high-risk patients. It works by binding to the spike protein of SARS-CoV-2, blocking the virus from entering human cells and inhibiting replication. The main types of clinical indications in regkirona (regdanvimab) are mild-to-moderate covid-19, severe covid-19, prevention of covid-19 progression, and post-exposure prophylaxis. Mild-to-moderate COVID-19 refers to cases with symptoms such as fever, cough, and fatigue that are manageable at home, with moderate cases involving some shortness of breath but not requiring intensive medical care. It is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, catering to various end users such as pediatric, adult, and geriatric.

Regkirona (regdanvimab) Market Segmentation

The regkirona (regdanvimab) market covered in this report is segmented – 1) By Clinical Indication: Mild-To-Moderate COVID-19; Severe COVID-19; Prevention Of COVID-19 Progression; Post-Exposure Prophylaxis 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies 3) By End User: Pediatric; Adult; Geriatric

Shingrix (Zostavax) Market Definition

Shingrix (Zostavax) refers to a vaccine designed to prevent shingles (herpes zoster), a painful rash caused by the reactivation of the varicella-zoster virus. It is used for immunizing adults, particularly those aged 50 and older, to reduce the risk of developing shingles and its complications. The main types of formulation in shingrix (zostavax) are recombinant vaccines (shingrix) and live-attenuated vaccines (zostavax). Recombinant vaccine (shingrix) refers to a non-live vaccine developed using recombinant DNA technology to prevent shingles, which stimulates the immune system by introducing a protein from the varicella-zoster virus, providing strong protection against the disease. The indications include shingles prevention and post-herpetic neuralgia with distribution channels such as Hospital Pharmacy and retail pharmacy.

Shingrix (Zostavax) Market Segmentation

The shingrix (zostavax) market covered in this report is segmented – 1) By Formulation: Recombinant Vaccine (Shingrix); Live Attenuated Vaccine (Zostavax) 2) By Indication: Shingles Prevention; Post-Herpetic Neuralgia 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy